All News

arthritis.RA_.Xray_.hands_.jpg (keep)

Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis

Jack Cush, MD

Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article
pill,pain,med,hand

Pain and Opioid Updates

Jack Cush, MD

Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids.



MMWR April 14, 2023

Read Article
computer screen safety

RA Patients on Biologics and tsDMARDs are still High Risk

Jack Cush, MD

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Read Article
RA,polyarticular,black,rheumatoid

Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis

Jack Cush, MD

A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.

Read Article
hospital-834152_640.jpg

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

Jack Cush, MD

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year. 

Read Article
guidelines.jpg (keep)

British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline

Jack Cush, MD

British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.

Read Article
warning, caution

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

Jack Cush, MD

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Read Article
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC

Links:

Dr. John Cush RheumNow ( View Tweet)
RA Patients on Biologics and tsDMARDs are still High Risk A new Swedish ARTIS registry study of key safety outcomes in RA patients receiving either targeted synthetic or b/ts DMARDs, including JAKi, has been updated and affirms previously held risks. https://t.co/mqfP4deGJv https://t.co/m43GSRlrct

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us April 18 for: Private Practice & Academia In this session, our panelists will address the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/BrWG57mRRG https://t.co/A0pzEvJ3cu

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate-induced pneumonitis (0.3% risk) is different than RA-ILD. MTX does not increase odds of RA-ILD. @jeffsparks @UTSW_Rheum https://t.co/JV1CcB0sLP
Dr. John Cush RheumNow ( View Tweet)
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now. https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV

Links:

Dr. John Cush RheumNow ( View Tweet)
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks https://t.co/rMEqodKdVN https://t.co/OT0gRRADIc

Links:

Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field. https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL

Links:

Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor. Sign up to attend our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN

Links:

Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×